Boston Oncology Arabia, a bio-generic medication manufacturer situated in Riyadh, Saudi Arabia, has secured a USD 35 million investment. The money was invested by TVM Capital.
The company plans to utilise the money to complete fill and finish manufacturing at its regional production plant in Sudair Industrial City, as well as to improve its transition into full formulation.
Read also – Indonesia-Based Xurya secures $55 Million in Funding
To increase the company’s access to foreign suppliers, TVM Capital Healthcare will also offer strategic support and make use of its extensive global network.
Under the direction of its founder and CEO, Abdullah Baaj, Boston Oncology Arabia develops and produces locally treatments with international licences, hence providing essential medications for life-threatening illnesses.
Read also – Bangladesh Based Tiger New Energy Raises $3.5 Million In Funding
By providing care medications through adaptable, local production facilities and utilising its global connections to get licences from Western and Eastern markets, it is helping to fulfil a significant objective of Saudi Arabia’s Vision 2030.
Abdullah Baaj said “Boston Oncology Arabia’s localization model is specifically designed to create value in complex and competitive markets. TVM Capital Healthcare’s support enables us to strengthen our position and bring cutting-edge, specialized manufacturing to the GCC and MENA region, impacting the lives of millions of patients.”
About Boston Oncology Arabia
Boston Oncology, an innovative biogenerics company, redefines excellence in licencing, local development, production, and distribution of US-quality pharmaceuticals across therapeutic categories.
